Hematopoietic progenitor cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilization
被引:11
作者:
Bertolini, F
论文数: 0引用数: 0
h-index: 0
机构:Pavia Med Ctr, IRCCS Maugeri Fdn, Div Med Oncol & Expt Med, I-27100 Pavia, Italy
Bertolini, F
Lanza, A
论文数: 0引用数: 0
h-index: 0
机构:Pavia Med Ctr, IRCCS Maugeri Fdn, Div Med Oncol & Expt Med, I-27100 Pavia, Italy
Lanza, A
Peccatori, F
论文数: 0引用数: 0
h-index: 0
机构:Pavia Med Ctr, IRCCS Maugeri Fdn, Div Med Oncol & Expt Med, I-27100 Pavia, Italy
Peccatori, F
Zibera, C
论文数: 0引用数: 0
h-index: 0
机构:Pavia Med Ctr, IRCCS Maugeri Fdn, Div Med Oncol & Expt Med, I-27100 Pavia, Italy
Zibera, C
Gibelli, N
论文数: 0引用数: 0
h-index: 0
机构:Pavia Med Ctr, IRCCS Maugeri Fdn, Div Med Oncol & Expt Med, I-27100 Pavia, Italy
Gibelli, N
Perotti, C
论文数: 0引用数: 0
h-index: 0
机构:Pavia Med Ctr, IRCCS Maugeri Fdn, Div Med Oncol & Expt Med, I-27100 Pavia, Italy
Perotti, C
Da Prada, GA
论文数: 0引用数: 0
h-index: 0
机构:Pavia Med Ctr, IRCCS Maugeri Fdn, Div Med Oncol & Expt Med, I-27100 Pavia, Italy
Da Prada, GA
Torretta, L
论文数: 0引用数: 0
h-index: 0
机构:Pavia Med Ctr, IRCCS Maugeri Fdn, Div Med Oncol & Expt Med, I-27100 Pavia, Italy
Torretta, L
Corocchio, E
论文数: 0引用数: 0
h-index: 0
机构:Pavia Med Ctr, IRCCS Maugeri Fdn, Div Med Oncol & Expt Med, I-27100 Pavia, Italy
Corocchio, E
Martinelli, G
论文数: 0引用数: 0
h-index: 0
机构:Pavia Med Ctr, IRCCS Maugeri Fdn, Div Med Oncol & Expt Med, I-27100 Pavia, Italy
Martinelli, G
della Cuna, GR
论文数: 0引用数: 0
h-index: 0
机构:Pavia Med Ctr, IRCCS Maugeri Fdn, Div Med Oncol & Expt Med, I-27100 Pavia, Italy
della Cuna, GR
机构:
[1] Pavia Med Ctr, IRCCS Maugeri Fdn, Div Med Oncol & Expt Med, I-27100 Pavia, Italy
[2] IRCCS San Matteo Hosp, Blood Transfus Unit, Pavia, Italy
[3] IRCCS European Inst Oncol, Div Med Oncol, Milan, Italy
breast cancer;
G-CSF;
mobilization;
stem cells;
transplantation;
D O I:
10.1023/A:1008226428543
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Background: We compared hematopoietic progenitor cell (HPC) collection and neoplastic cell contamination in breast cancer patients given cyclophosphamide (CTX) plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilization. Patients and methods: In 57 stage II-III breast cancer patients, CD34+ cells, colony-forming units-granulocyte macrophage (CFU-GM), early HPC and breast cancer cells were counted in HPC collections obtained after CTX plus G-CSF (n = 27) or G-CSF-alone mobilization (n = 30). Results. The CD34+ cell collection was about two-fold greater after CTX plus G-CSF mobilization (11.0 +/- 7.9 vs. 5.8 +/- 3.5 x 10(6)/kg, P < 0.001). Similarly, the total number of CFU-GM, CD34+CD38- cells and of week-5 cobblestone area forming cells (CAFC) collected was significantly higher in patients mobilized with CTX plus G-CSF. Breast cancer cells were found in the apheresis products of 22% of patients mobilized with CTX plus G-CSF and in 10% of patients mobilized with G-CSF alone (P = 0.36). Of seven patients who failed G-CSF-alone mobilization and eventually underwent chemotherapy plus G-CSF mobilization, none had cytokeratin-positive cells after G-CSF mobilization, whereas four out of seven had cytokeratin-positive cells after chemotherapy plus G-CSF (P = 0.07 by chi(2) test). Conclusion: The CTX plus G-CSF mobilization protocol was associated with a significantly higher HPC collection. However, this benefit was not accompanied by a reduction in the incidence of tumor-contaminated HPC graft.